{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+II+Non-small+Cell+Lung+Cancer",
    "query": {
      "condition": "Stage II Non-small Cell Lung Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1091,
    "total_pages": 110,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+II+Non-small+Cell+Lung+Cancer&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T06:45:55.323Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01822496",
      "title": "Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III Non-Small Cell Lung Cancer AJCC v7",
        "Stage IIIA Non-Small Cell Lung Cancer AJCC v7",
        "Stage IIIB Non-Small Cell Lung Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Crizotinib",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2013-11-04",
      "completion_date": "2018-06-04",
      "has_results": true,
      "last_update_posted_date": "2019-08-05",
      "last_synced_at": "2026-05-22T06:45:55.323Z",
      "location_count": 174,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 137 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01822496"
    },
    {
      "nct_id": "NCT00900302",
      "title": "OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "protein expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "Up to 120 Years"
      },
      "enrollment_count": 98,
      "start_date": "2005-04",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2016-02-10",
      "last_synced_at": "2026-05-22T06:45:55.323Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00900302"
    },
    {
      "nct_id": "NCT00055757",
      "title": "Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage IIIB Non-small Cell Lung Cancer",
        "Stage IV Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "tipifarnib",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2003-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-04",
      "last_synced_at": "2026-05-22T06:45:55.323Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00055757"
    },
    {
      "nct_id": "NCT00073151",
      "title": "A Study of ABT-751 in Patients With Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "ABT-751",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2003-09",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2007-11-29",
      "last_synced_at": "2026-05-22T06:45:55.323Z",
      "location_count": 17,
      "location_summary": "Miami, Florida • New Port Richey, Florida • Chicago, Illinois + 14 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00073151"
    },
    {
      "nct_id": "NCT00003269",
      "title": "Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Drug/Agent Toxicity by Tissue/Organ",
        "Lung Cancer",
        "Lymphoma",
        "Ovarian Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "amifostine trihydrate",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Scripps Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "1998-02",
      "completion_date": "2001-01",
      "has_results": false,
      "last_update_posted_date": "2011-01-10",
      "last_synced_at": "2026-05-22T06:45:55.323Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003269"
    },
    {
      "nct_id": "NCT02444741",
      "title": "Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Malignant Solid Neoplasm",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Stage IV Lung Non-Small Cell Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "3-Dimensional Conformal Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Proton Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2015-09-17",
      "completion_date": "2026-02-17",
      "has_results": true,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-05-22T06:45:55.323Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02444741"
    },
    {
      "nct_id": "NCT03421353",
      "title": "AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumours"
      ],
      "interventions": [
        {
          "name": "AZD9150",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "5-Flourouracil",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 76,
      "start_date": "2018-02-07",
      "completion_date": "2024-03-28",
      "has_results": false,
      "last_update_posted_date": "2024-08-21",
      "last_synced_at": "2026-05-22T06:45:55.323Z",
      "location_count": 6,
      "location_summary": "Lafayette, Indiana • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more",
      "locations": [
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03421353"
    },
    {
      "nct_id": "NCT05948462",
      "title": "Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Lorlatinib",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin or Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2023-11",
      "completion_date": "2025-09",
      "has_results": false,
      "last_update_posted_date": "2023-12-13",
      "last_synced_at": "2026-05-22T06:45:55.323Z",
      "location_count": 5,
      "location_summary": "Denver, Colorado • Asheville, North Carolina • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Asheville",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05948462"
    },
    {
      "nct_id": "NCT00871923",
      "title": "Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Brain Cancer"
      ],
      "interventions": [
        {
          "name": "Tarceva (Erlotinib hydrochloride)",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 44,
      "start_date": "2009-03-26",
      "completion_date": "2019-12-04",
      "has_results": true,
      "last_update_posted_date": "2021-09-16",
      "last_synced_at": "2026-05-22T06:45:55.323Z",
      "location_count": 2,
      "location_summary": "Tucson, Arizona • Houston, Texas",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00871923"
    },
    {
      "nct_id": "NCT04396535",
      "title": "Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lung Non-Small Cell Carcinoma",
        "Stage III Lung Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Bintrafusp Alfa",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2020-10-23",
      "completion_date": "2023-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-11-17",
      "last_synced_at": "2026-05-22T06:45:55.323Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04396535"
    }
  ]
}